secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMERICA INC (BMRA)
CIK:        0000073290
Form:       8-K
Filed at:   2021-12-16T23:59:59+00:00
Accession:  0001513162-21-000162
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomerica preliminary Q2 revenue $4.6M (+238% YoY); backlog $4M; InFoods trial data due Jan 2022
--------------------------------------------------------------------------------

- Revenue approximately $4.6M for Q2 ended Nov 30, 2021, up 238% from $1.4M a year ago, driven by COVID test demand.
- Operating loss expected between $0.9M and $1.3M; logistics constraints and higher shipping costs hurt margins.
- Backlog of unfilled orders exceeds $4.0M entering Q3; cash balance over $7M, partly from prepayments.
- InFoods IBS clinical trial data collection complete; topline results expected by end of January 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/73290/000151316221000162/0001513162-21-000162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/73290/000151316221000162/bmra-20211216.htm
  HTML page:      https://secwatch.observer/filing/0001513162-21-000162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer